NASDAQ · NXL
Healthcare · Medical - Devices
$4.82
Down-$0.05 (-1.03%)
Updated Sep 14, 2026, 3:19 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NXL closed at $4.82 after 19 trading sessions, up 1317.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $4.91 | $4.97 | $4.5397 | $4.82 | 14.61K |
| Sep 10, 2026 | $4.90 | $5.13 | $4.62 | $4.87 | 57.27K |
| Sep 9, 2026 | $4.76 | $5.4899 | $4.76 | $5.05 | 9.71K |
| Sep 8, 2026 | $4.99 | $5.02 | $4.5101 | $4.79 | 8.54K |
| Sep 4, 2026 | $5.36 | $5.36 | $4.72 | $5.06 | 14.42K |
| Sep 3, 2026 | $6.02 | $6.36 | $5.24 | $5.36 | 38.64K |
| Sep 2, 2026 | $6.77 | $6.80 | $5.9377 | $6.19 | 27.87K |
| Sep 1, 2026 | $7.10 | $7.15 | $6.33 | $6.80 | 7.67K |
| Aug 31, 2026 | $6.28 | $7.69 | $6.25 | $7.23 | 31.4K |
| Aug 28, 2026 | $7.65 | $7.788 | $7.50 | $7.50 | 7.42K |
| Aug 27, 2026 | $7.20 | $8.097 | $6.603 | $7.644 | 40.25K |
| Aug 26, 2026 | $9.30 | $9.393 | $8.85 | $8.85 | 5.47K |
| Aug 25, 2026 | $9.396 | $9.60 | $9.063 | $9.561 | 3.7K |
| Aug 24, 2026 | $0.3301 | $0.341 | $0.311 | $0.3154 | 253.28K |
| Aug 21, 2026 | $0.3325 | $0.3326 | $0.3275 | $0.3321 | 88.65K |
| Aug 20, 2026 | $0.3394 | $0.3499 | $0.325 | $0.3306 | 124.87K |
| Aug 19, 2026 | $0.3327 | $0.3399 | $0.33 | $0.33 | 112.63K |
| Aug 18, 2026 | $0.342 | $0.3499 | $0.3333 | $0.3333 | 58.18K |
| Aug 17, 2026 | $0.34 | $0.3599 | $0.335 | $0.34 | 82.39K |
The latest Smart Investors Daily articles mentioning NXL.
NXL research
Company profile and research snapshot.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 24, 2025 | Maxim Group | Buy | — |
| Dec 5, 2024 | Maxim Group | Hold | — |
| Oct 9, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.
Yahoo · Sep 3, 2026
Further analysis of ADAS-Cog data from the Company’s randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer’s Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer’s patients One half of evaluable active-arm participants achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with domain-level gains in comprehension, memory and language function still evident three m
ChartMill · Jun 25, 2026
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Yahoo · Jun 23, 2026
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil Award-winning research evaluated Nexalin’s DIFS™ 15 mA, 77.5 Hz platform for insomnia symptoms in patients with comorbid anxiety, with the primary reported finding being a significant, durable improvement in sleep quality Independent scientific recognition further
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NXL.
